FDA’s Second Delay on Lilly’s Prasugrel is a Headscratcher

Eli Lilly and partner Daiichi Sankyo said the FDA still hasn't finished its review of the anti-clotting drug. There were few details, but every minute of delay helps Bristol-Myers and Sanofi-Aventis.